ATE Stock

It seems fair to say that biotech hasn’t been the hottest of fields for much of this year. Money c... Read More

Stefan Quenneville of Echelon Capital Markets has lowered his expectations for Antibe Therapeutics (... Read More

A safety issue with its lead drug has chopped a big hole in the share price for Canadian pharma comp... Read More

Keep your eyes on the prize, that’s the message for investors looking at Antibe Therapeutics (Anti... Read More

Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has had a turbulent coup... Read More

Investment bankers Paradigm Capital launched coverage on Wednesday of drug developer Antibe Therapeu... Read More

Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has performed well both ... Read More

Canadian Life Sciences stocks have been on a roller coaster ride so far in 2019. The sector, which i... Read More

Echelon Wealth Partners analyst Douglas Loe is holding steady on his investment thesis for clinical ... Read More

Echelon Wealth Partners analyst Douglas Loe is staying bullish on clinical stage drug developer Anti... Read More

In an update to clients Wednesday, Echelon Wealth Partners analyst Douglas Loe remains bullish on cl... Read More

In a research update on Monday, Echelon Wealth Partners analyst Douglas Loe reiterated his “Specul... Read More

Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart TSXV:ATE) may keep trading sideways for ... Read More

In a coverage launch on Thursday, Echelon Wealth Partners analyst Douglas Loe says clinical stage dr... Read More

Tiny Antibe Therapeutics (TSXV:ATE) may be set to shake up the massive NSAID market, says M Partners... Read More